RARE•benzinga•
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
Summary
Ultragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga